KDM1A Antibody, HRP conjugated

說明書

中文名稱：

KDM1A兔多克隆抗體, HRP偶聯(lián)
貨號：

CSB-PA525314HB01HU
規(guī)格：

￥880
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) KDM1A Polyclonal antibody
Uniprot No.：

O60341
基因名：

KDM1A
別名：

Amine oxidase (flavin containing) domain 2 antibody; Amine oxidase, flavin containing, 2 antibody; AOF2 antibody; BHC110 antibody; BRAF35 HDAC complex protein BHC110 antibody; BRAF35-HDAC complex protein BHC110 antibody; BRAF35/HDAC complex, 110-kD subunit antibody; CPRF antibody; EC1 antibody; FAD binding protein BRAF35 HDAC complex, 110 kDa subunit antibody; Flavin-containing amine oxidase domain-containing protein 2 antibody; KDM 1 antibody; KDM1 antibody; Kdm1a antibody; KDM1A_HUMAN antibody; KIAA0601 antibody; LSD 1 antibody; LSD1 antibody; Lysine (K) specific demethylase 1 antibody; Lysine (K) specific demethylase 1A antibody; Lysine demethylase 1A antibody; Lysine specific histone demethylase 1 antibody; Lysine specific histone demethylase 1A antibody; Lysine-specific demethylase 1 antibody; Lysine-specific demethylase 1A antibody; Lysine-specific histone demethylase 1A antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Lysine-specific histone demethylase 1A protein (100-150AA)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

HRP
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA
Protocols：

ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Histone demethylase that can demethylate both 'Lys-4' (H3K4me) and 'Lys-9' (H3K9me) of histone H3, thereby acting as a coactivator or a corepressor, depending on the context. Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. Acts as a corepressor by mediating demethylation of H3K4me, a specific tag for epigenetic transcriptional activation. Demethylates both mono- (H3K4me1) and di-methylated (H3K4me2) H3K4me. May play a role in the repression of neuronal genes. Alone, it is unable to demethylate H3K4me on nucleosomes and requires the presence of RCOR1/CoREST to achieve such activity. Also acts as a coactivator of androgen receptor (AR)-dependent transcription, by being recruited to AR target genes and mediating demethylation of H3K9me, a specific tag for epigenetic transcriptional repression. The presence of PRKCB in AR-containing complexes, which mediates phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag that prevents demethylation H3K4me, prevents H3K4me demethylase activity of KDM1A. Demethylates di-methylated 'Lys-370' of p53/TP53 which prevents interaction of p53/TP53 with TP53BP1 and represses p53/TP53-mediated transcriptional activation. Demethylates and stabilizes the DNA methylase DNMT1. Required for gastrulation during embryogenesis. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. Effector of SNAI1-mediated transcription repression of E-cadherin/CDH1, CDN7 and KRT8. Required for the maintenance of the silenced state of the SNAI1 target genes E-cadherin/CDH1 and CDN7.
基因功能參考文獻：
1. the role of the LSD1 complex in the reactivation of HIV-1 transcription from latency PMID: 30105631
2. LSD1 and JMJD2C disable oncogenic Ras- or Braf-induced senescence by enabling the expression of E2F target genes PMID: 29438700
3. LSD1 inhibition may serve as a promising epigenetic adjuvant therapy to subvert its pleiotropic roles in breast cancer progression and treatment resistance. PMID: 29311580
4. Results show that KDM1A is upregulated in the gastric cancer (GC) cells and tissues. Its expression is negatively modulated by mir329 which directly targets its 3'utr. PMID: 29130516
5. FOXP4-AS1 is overexpressed in osteosarcoma (OS), and is the independent risk factor in OS prognosis. Upregulated FOXP4-AS1 promotes the proliferation, migration and cell cycle, but inhibits apoptosis of OS cells. Furthermore, FOXP4-AS1 participates in the development and progression of OS by downregulating LATS1 via binding to LSD1 and EZH2. PMID: 29859193
6. Enhancer of Zeste Homolog 2 (EZH2), SET domain, bifurcated 1 protein (SETDB1), lysine-specific histone demethylase 1 (LSD1), histone H3 methylation (H3K9me3 and H3K27me3) expression are altered in colorectal cancer (CRC) and may play a role in colorectal carcinogenesis. PMID: 30105513
7. the crystal structure of LSD1 in complex with the inhibitor 4-[5-(Piperidin-4-ylmethoxy)-2-(p-tolyl)pyridin-3-yl]benzonitrile at 2.96 A, is reported. PMID: 29949906
8. This study showed that tetrahydrofolate stably binds to the LSD1/CoREST complex, in its open conformation, at its entrance. PMID: 29161028
9. Study reveals LSD1 as a molecular rheostat selectively regulating H3K9 demethylation at cell cycle gene loci, thereby representing a key player in oncogenesis and a viable target for cancer therapy. PMID: 28991226
10. KDM1A is a unique epigenetic modifier with the ability to maintain interactions with a variety of different protein complexes, noncoding RNAs, microRNAs, and transcription factors. The functional significance of KDM1A is maintained by its interactions at multiple sites in the genome, particularly its binding to promoters and enhancers. [review] PMID: 29921310
11. our findings identified LSD1 as a novel negative regulator of autophagy through the mTOR signaling pathway in ovarian cancer HO8910 cells and indicated that LSD1 may function as a driving factor of ovarian cancer progression via deregulating autophagy. PMID: 29749504
12. a small-molecule LSD1 inhibitor-SP-2509-blocks important demethylase-independent functions and suppresses castration-resistant prostate cancer cell viability demonstrates the potential of LSD1 inhibition in this disease. PMID: 29581250
13. expression of the nearby cyclindependent kinase inhibitor 1C (CDKN1C) gene was revealed to be upregulated after SP3 knockdown in cells that possessed non-risk alleles. This suggests that CDKN1C is potentially one of the functional targets of SNP rs163184, which modulates the binding activity of the locus for Sp3 and Lsd1/Kdm1a PMID: 29207083
14. Silencing of LSD1 is capable of removing the mono- and dimethyl groups from H3K4, and upregulating the histone acetylation of H3 in JeKo1 and MOLT4 cells. The silencing of LSD1 inhibited cell growth and induced cell apoptosis. PMID: 28627608
15. LSD1 and ERRalpha coregulate several target genes involved in cell migration, including the MMP1 matrix metallo-protease, also activated through H3K9 demethylation at the transcriptional start site. PMID: 28348226
16. concomitant LSD1 and HDAC inhibition synergistically induces cell death in rhabdomyosarcoma cells by shifting the ratio of pro- and antiapoptotic BCL-2 proteins in favor of apoptosis, thereby engaging the intrinsic apoptotic pathway PMID: 28617441
17. Results show that LSD1 protein level is elevated in prostate tumors (PCa) and correlate with faster tumor growth in xenograft mouse models. Knockdown of LSD1 reduces PCa cell viability, and gene expression data suggest a dual coregulatory role of LSD1 for VDR, acting as a coactivator and corepressor in a locus-specific manner. PMID: 28811844
18. Study showed that repressed HBV cccDNA chromatin state is activated by LSD1 by demethylating H3K9. Also, LSD1 was shown to be recruited to viral promoters in an HBx dependent manner. PMID: 27174370
19. LSD1 knockdown has a broad effect on histone lysine methylation. PMID: 28601046
20. analysis of a novel cellular stress response mechanism in cancer cells and a key role of LSD1/SIRT1/KU70 dynamic interaction in regulating DNA repair and mutation acquisition PMID: 27384990
21. Patients with mutations 6 showed higher rate of achieving major molecular response than those<6 (P=0.0381). Mutations in epigenetic regulator, ASXL1, TET2, TET3, KDM1A and MSH6 were found in 25% of patients. TET2 or TET3, AKT1 and RUNX1 were mutated in one patient each. ASXL1 was mutated within exon 12 in three cases PMID: 28452984
22. Study demonstrated that LSD1 in cooperation with MYCN controls cell migration and invasiveness of neuroblastoma cells through transcription regulation of the metastatic suppressor NDRG1. PMID: 27894074
23. Results show that LSD1 could directly bind to the promoter of P21, inducing H3K4me2 demethylation. PMID: 28209170
24. The autophagy induced by 2-PCPA requires LC3-II processing machinery..2-PCPA treatment induces the change of global gene expression program, including a series of autophagy-related genes, such as SQSTM1/p62. Taken together, our data indicate that KDM1A/LSD1 inhibitors induce autophagy through affecting the expression of autophagy-related genes and in a BECN1-independent manner PMID: 28800922
25. LSD1 is specifically mislocalized to pathological protein aggregates in the Alzheimer's disease and frontotemporal dementia patients brain. PMID: 28993646
26. these results demonstrate crosstalk between the lysine demethylase KDM1A and the DNA methyltransferase DNMT1, which could be involved in carcinogenesis independently of its role in DNA methylation PMID: 27449289
27. LSD1 inhibition with HCI-2509 decreases the c-MYC level in poorly differentiated prostate cancer cell lines. PMID: 27349498
28. Such a relatively simple strategy uncovered two new classes of LSD1 inhibitors , which reveal unexpected binding modes at the same protein surface, establishing specific and common contacts, and highlight novel routes for the development of compounds targeting epigenetic processes. PMID: 27626075
29. we show that KDM1A promotes cancer metastasis in non-small cell lung cancer cells by repressing TIMP3 (tissue inhibitor of metalloproteinase 3) expression. PMID: 27058897
30. Results show that LSD1 expression was upregulated in breast carcinoma and, induced EMT in breast cancer cells through demethylation of H3K4me at the E-cadherin promoter. Its phosphorylation at Ser112 is crucial for these functions. PMID: 27572339
31. LSD1 directly associates with the promoter of the HEYL gene. PMID: 27018646
32. LSD1 controls autophagy in neuroblastoma cells through SESN2 transcription regulation. PMID: 28783174
33. Mechanistic investigations showed that LINC01133 could interact with EZH2, LSD1 and recruit them to KLF2, P21 or E-cadherin promoter regions to repress their transcription. PMID: 26840083
34. estrogen induced TFPI-2 expression in MCF7 cells is mediated by ERalpha and also by the action of LSD1. PMID: 28088469
35. CENPE was regulated by the co-binding of LSD1 and AR to its promoter, which was associated with loss of RB1 in CRPC. PMID: 28916652
36. RBPJ interacts with L3MBTL3 to promote repression of Notch signaling via histone demethylase KDM1A. PMID: 29030483
37. High LSD1 expression is associated with small-cell lung cancer. PMID: 28667074
38. The role of LSD1 in the EMT process. PMID: 28720390
39. p53-CTD inhibits LSD1 activity and that the direct association between the two proteins can contribute to their functional cross-talk. PMID: 28784588
40. LSD1 is a key regulator of HIF1alpha/VEGF-mediated tumor angiogenesis by antagonizing the crosstalk between PTMs involving HIF1alpha protein degradation. PMID: 28534506
41. This study identified histone modification by SUMO as the first post-translational modification that stimulates intranucleosomal demethylation by the developmentally critical LSD1-CoREST complex. PMID: 28832116
42. These findings provide insight into the regulation of LSD1 and Epithelial-to-Mesenchymal Transition (EMT) and identify MOF as a critical suppressor of EMT and tumor progression. PMID: 27292636
43. High LSD1 expression is associated with colon cancer. PMID: 28121627
44. results demonstrate that CoREST and LSD1 downregulate the Notch pathway in the developing cerebral cortex PMID: 27112428
45. LSD1 is a primary and positive regulator of the HPV16 E7-induced epithelial-mesenchymal transition in cervical cancer PMID: 27894088
46. KDM1A inhibitors may be utilized to alleviate acquired resistance to sorafenib in hepatocellular carcinoma cells. PMID: 28377178
47. This study identified the lysine-specific demethylase KDM1A as a novel interaction partner of ZEB2 and demonstrated that mouse and human T-cell acute lymphoblastic leukemia cells with increased ZEB2 levels critically depend on KDM1A activity for survival. PMID: 28069602
48. LSD1 overexpression is associated with non-small cell lung cancer. PMID: 28223039
49. a model in which the EZH2/HOXA11-AS/LSD1 complex and HOXA11-AS/miR-1297/EZH2 cross-talk serve as critical effectors in gastric cancer tumorigenesis and progression. PMID: 27651312
50. these results demonstrate the relevance of LSD1 in gene regulation and how even moderate alterations in its stability, catalytic activity and binding properties can strongly affect organism development. PMID: 27094131
顯示更多

收起更多
相關(guān)疾病：

Cleft palate, psychomotor retardation, and distinctive facial features (CPRF)
亞細胞定位：

Nucleus.
蛋白家族：

Flavin monoamine oxidase family
組織特異性：

Ubiquitously expressed.
數(shù)據(jù)庫鏈接：

HGNC: 29079

OMIM: 609132

KEGG: hsa:23028

STRING: 9606.ENSP00000383042

UniGene: Hs.591518

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human